L19IL2

DRUG4 trials

Sponsors

Philogen S.p.A.

Conditions

Advanced Solid TumoursFAPLocally Advanced Basal Cell CarcinomaMelanoma Stage IIIMelanoma Stage IV

Phase 1

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

CompletedNCT01058538

Philogen S.p.A.Advanced Solid Tumours

Start: 2005-11-30End: 2009-11-30Updated: 2014-02-25

A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

RecruitingNCT06640413

Philogen S.p.A.FAP

Start: 2025-10-31End: 2028-12-31Target: 56Updated: 2026-01-14

Phase 2

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

RecruitingNCT06284590

Philogen S.p.A.Melanoma Stage III, Melanoma Stage IV

Start: 2024-07-12End: 2028-07-31Target: 162Updated: 2024-10-26

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Not yet recruitingNCT07227350

Philogen S.p.A.Locally Advanced Basal Cell Carcinoma

Start: 2026-02-01End: 2031-02-01Target: 180Updated: 2026-03-10